Targeted RNA degradation allows precision repurposing of protein-targeted small molecule medicines to RNA
AssigneeUniversity of Florida Research Foundation, Inc.
InventorMatthew D. Disney
Life of this patent
Estimating the term…
Abstract
The protein targeted medicine, Dovitinib, has been repurposed to target a non-coding RNA by using selection and computational drug design via Inforna. Selectivity was achieved for pre-miR-21 by endowing the medicine with the ability to recruit RNA quality control enzymes to cleave the target.
Claims22
A method for targeting an RNA entity comprising contacting the RNA entity with a binding composition wherein
- the RNA entity is (1) pre-miR-21, (2) an oncogenic cell line containing pre-miR-21, the cell line being a TNBC breast cancer cell line, MDA-MD-231 breast cancer cell line, prostate cancer cell line, or non-small-cell lung carcinoma cell line, (3) an animal host having an oncogenic cell line associated with pre-miR-21, (4) a human having an oncogenic malignancy associated with pre-miR-21, (5) an animal host having Alport Syndrome kidney disease, (6) a human having Alport Syndrome kidney disease or any disease in which pre-miR-21 is causative or contributive;
- and,
- the binding composition comprises at least a Ribotac-Dovitinib having a formula of Compound 2 or a Protac-Dovitinib having a formula of Compound 3
A composition comprising Compound 2 or Compound 3 or any combination thereof wherein
A method for determining a binding site on a pre-miRNA for Dovitinib comprising contacting the pre-miRNA with Compound 4 to form a complex, irradiating the complex, contacting the complex with a biotin azide to form a biotin-triazolyl-complex, and isolating the biotin-triazolyl complex with a streptavidin substance, wherein Compound 4 has the formula:
Dependencies are inferred from the claim text.